G

Galderma Group AG
SIX:GALD

Watchlist Manager
Galderma Group AG
SIX:GALD
Watchlist
Price: 86.74 CHF 1.87% Market Closed
Market Cap: 20.6B CHF
Have any thoughts about
Galderma Group AG?
Write Note

Galderma Group AG
Cash

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Galderma Group AG
Cash Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash CAGR 3Y CAGR 5Y CAGR 10Y
G
Galderma Group AG
SIX:GALD
Cash
367.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Transocean Ltd
NYSE:RIG
Cash
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
M
MoonLake Immunotherapeutics
NASDAQ:MLTX
Cash
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Sealsq Corp
NASDAQ:LAES
Cash
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
T
TalkPool AG
STO:TALK
Cash
€809.9k
CAGR 3-Years
-23%
CAGR 5-Years
-11%
CAGR 10-Years
N/A
R
R&S Group Holding AG
SIX:RSGN
Cash
CHf198m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Galderma Group AG
Glance View

Market Cap
20.6B CHF
Industry
N/A

Galderma Group AG is a global leader in dermatology, committed to delivering innovative solutions that enhance the health and beauty of skin. Founded in 1981, the company has cultivated a rich portfolio of products spanning prescription medications and consumer skin health brands. It operates under key brands like Restylane, used for aesthetic solutions, and Cetaphil, known for its gentle skincare products. With a strong emphasis on research and development, Galderma consistently invests in cutting-edge technologies and clinical advancements to meet the diverse needs of its patients and consumers worldwide. As the skin health market continues to expand—driven by increasing awareness of skin conditions and the rise in demand for aesthetic treatments—Galderma is strategically positioned to capture significant growth opportunities. The company's proactive approach to sustainability and focus on patient-centric solutions further solidify its reputation in the industry. For investors, Galderma represents not just a steady performer in the healthcare sector, but also an innovative player navigating the evolving landscape of dermatology. By prioritizing both efficacy and consumer satisfaction, Galderma is not only promoting healthier skin but is also capitalizing on a rapidly growing market—making it a compelling addition to any investment portfolio.

GALD Intrinsic Value
Not Available
G

See Also

What is Galderma Group AG's Cash?
Cash
367.8m

Based on the financial report for Dec 31, 2023, Galderma Group AG's Cash amounts to 367.8m .

What is Galderma Group AG's Cash growth rate?
Cash CAGR 1Y
57%

Over the last year, the Cash growth was 57%.

Back to Top